TCGA-AN-A0AT-01A-11R-A034-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 0
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.680
- E2F_TARGETS+0.650
- MYC_TARGETS_V1+0.650
- G2M_CHECKPOINT+0.540
- MTORC1_SIGNALING+0.390
- SPERMATOGENESIS+0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- DNA_REPAIR+0.280
- OXIDATIVE_PHOSPHORYLATION+0.260
- MITOTIC_SPINDLE+0.240
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.470
- ESTROGEN_RESPONSE_EARLY-0.460
- HEDGEHOG_SIGNALING-0.340
- UV_RESPONSE_DN-0.310
- PANCREAS_BETA_CELLS-0.300
- ESTROGEN_RESPONSE_LATE-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- MYOGENESIS-0.240
- APOPTOSIS-0.230
- INTERFERON_GAMMA_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A18T-01A-11R-A12D-07 | — | E | 0.885 |
| 2 | 20030039.TNBC | — | E | 0.861 |
| 3 | TCGA-C8-A1HJ-01A-11R-A13Q-07 | — | E | 0.843 |
| 4 | 20040122.TNBC | — | E | 0.840 |
| 5 | TCGA-D8-A143-01A-11R-A115-07 | — | C | 0.837 |
| 6 | de5a4588-05ec-461f-9235-90611b01f4b6 | — | — | 0.822 |
| 7 | SRR17866823 | — | — | 0.820 |
| 8 | SRR8518329 | — | E | 0.820 |
| 9 | BSR_04_0077_A8_S97 | — | E | 0.816 |
| 10 | SRR1313140 | — | E | 0.816 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.680 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.650 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.650 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.370 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.030 | Idelalisib | — uncovered |